Prasugrel
5 customer reviewsPrasugrel is an antiplatelet medicine in the P2Y12 inhibitor class. It is for adults with acute coronary syndrome who have had PCI such as angioplasty or stent placement. It helps prevent clots by irreversibly blocking the platelet P2Y12 receptor to reduce platelet aggregation.
What is it?
Prasugrel is a potent antiplatelet medicine in the P2Y12 inhibitor class, used to reduce blood-clot risk in people with acute coronary syndrome who have had a coronary procedure such as angioplasty or stent placement. It is mainly used in adults where preventing platelet “stickiness” can lower the chance of thrombotic events like heart attack or ischaemic stroke. Prasugrel works by irreversibly blocking the platelet P2Y12 receptor, reducing platelet aggregation and clot formation.
Composition
Prasugrel tablets contain the active substance prasugrel (usually as prasugrel hydrochloride) in strengths such as 5 mg or 10 mg per tablet, plus inactive excipients that form the tablet core and coating.
How to use?
- Route: oral (swallow tablets with water)
- Loading dose: 60 mg once (given once, typically at start of therapy)
- Maintenance dose: 10 mg once daily
- Lower-dose option: 5 mg once daily (used when a reduced dose is prescribed)
- With food: may be taken with or without meals
- Duration: as prescribed by the cardiology specialist, commonly continued long term after the acute event
How does it work?
- Route: oral
- Typical initiation: 60 mg once (loading dose)
- Ongoing regimen: 10 mg once daily (or 5 mg once daily if a reduced dose is prescribed)
- Timing with meals: with or without food
- Treatment length: as directed, usually continued daily to maintain platelet inhibition
Indications
Prasugrel is used to prevent heart attacks, strokes, and other serious problems with the heart or blood vessels in patients with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI) such as angioplasty with stent placement. It is usually part of dual antiplatelet therapy (DAPT), commonly with aspirin, during the period your cardiologist considers your stent most vulnerable to thrombosis.
A practical way doctors frame it is simple: after a stent, the body can treat that metal scaffold like an “injury surface,” so platelet activity has to be controlled while the stent becomes covered and stabilised. WHO cardiovascular guidance continues to emphasise preventing recurrent atherothrombotic events after ACS as a key strategy to reduce avoidable deaths and disability [2].
This medicine is not used for quick symptom relief.
It is preventive treatment.
Comparison
Prasugrel, clopidogrel, and ticagrelor are all P2Y12 inhibitors, but they differ in activation, reversibility, and typical clinical positioning. Clinicians often think in terms of potency and predictability versus bleeding risk, then match the drug to the patient profile (age, prior stroke/TIA history, weight, need for surgery, and tolerance).
| Feature | Prasugrel | Clopidogrel / Ticagrelor |
|---|---|---|
| Activation & reversibility | Prodrug; irreversible platelet inhibition | Clopidogrel: prodrug; irreversible. Ticagrelor: active drug; reversible |
| Onset & potency (typical) | Faster, stronger platelet inhibition than clopidogrel in many patients | Clopidogrel: slower, more variable. Ticagrelor: fast, strong |
| Main limitation | Higher bleeding risk in certain groups | Clopidogrel: lower potency in some; Ticagrelor: side effects like dyspnoea in some |
A common real-world pattern in Nigeria is that doctors start with the guideline-supported option for ACS after PCI, then adjust when the patient’s bleeding history, affordability, or adherence barriers become clearer over follow-up. NICE guidance on ACS antiplatelet strategies discusses these agent-to-agent trade-offs and stresses tailoring to bleeding risk and clinical context rather than “one best pill” for everyone [3].
Contraindications
- Active bleeding (including gastrointestinal bleeding or intracranial haemorrhage)
- History of stroke or transient ischaemic attack (TIA)
- Hypersensitivity/allergy to prasugrel or tablet ingredients
Not recommended for
Do not use Prasugrel if you have bleeding that is happening now, such as stomach bleeding, bleeding in the brain, or blood you cannot explain. Avoid it if you have ever had a stroke or a “mini-stroke” (TIA), because the bleeding risk can outweigh the benefit. Tell your clinician early if you are planning surgery or major dental work, because your antiplatelet plan may need to be adjusted safely.
Side effects
Bleeding is the main risk with Prasugrel. It can show up as mild bruising, nosebleeds, or prolonged bleeding from small cuts, and it can also be internal and dangerous.
Commonly reported effects in practice include:
- Easy bruising or larger bruises from minor knocks
- Nosebleeds or gum bleeding when brushing teeth
- Longer bleeding time after shaving or small cuts
- Indigestion or stomach discomfort in some people
Seek urgent assessment for signs that suggest significant bleeding:
- Black, tarry stools or visible blood in stool
- Vomiting blood or material that looks like coffee grounds
- Severe headache, sudden weakness, confusion, or speech trouble
- Blood in urine, or very heavy menstrual bleeding
Allergic reactions can occur.
Facial swelling needs urgent care.
A pharmacist detail patients appreciate: bruises are expected, but new bruises plus tiredness and paleness can signal anaemia from occult bleeding, and it deserves a prompt review. Another nuance: dental work is a common trigger for bleeding scares; dentists often plan differently when they know a patient is on a P2Y12 inhibitor.
Common mistakes
The biggest problems I see are rarely about “the drug not working.” They are about inconsistent use, hidden bleeding risks, and unplanned procedures.
Common mistakes include:
- Stopping Prasugrel suddenly because bruising looked scary, without arranging a same-day clinical review
- Doubling the next dose after a missed dose, which increases bleeding risk without giving reliable protection
- Taking extra NSAIDs for pain (for example, ibuprofen or diclofenac) on top of Prasugrel, then being surprised by stomach bleeding
- Not telling a dentist or surgeon early, then facing last-minute cancellations or bleeding complications
- Mixing alcohol heavily during the first weeks after ACS, which can worsen falls, injuries, and bleeding consequences
A small but real detail: some people start using a razor blade for a close shave and then panic at the bleeding. Switching to an electric shaver can prevent that cycle of fear and missed doses.
Doctor opinions
Cardiologists tend to be direct about Prasugrel: it is chosen when the benefit of strong platelet inhibition after ACS and PCI is expected to outweigh bleeding risk. In day-to-day follow-up, doctors often watch three things closely: recurrent chest pain, adherence (missed doses), and bleeding signals like frequent nosebleeds or unexplained bruising.
One consistent clinical observation is that patients who “feel fine” are the most likely to skip doses. That’s understandable because Prasugrel is preventive, not symptom-driven. Another pattern: when a patient expects surgery or a major dental procedure, the cardiology team wants advance notice so antiplatelet planning can be coordinated safely.
Doctors also screen aggressively for prior stroke or transient ischaemic attack before choosing prasugrel, because that history changes the risk-benefit balance. NAFDAC safety communications around prescription medicines repeatedly emphasise patient-specific assessment and appropriate use under qualified prescribers for high-risk cardiovascular drugs [4].
Frequently asked questions
Prasugrel is absorbed and converted to an active metabolite quickly, with platelet inhibition beginning within hours of a dose, and stronger effects after loading regimens used around PCI. What patients feel day to day is usually nothing, because the target is platelet activity, not pain. If you are starting after a procedure, the hospital plan often specifies a loading dose then a daily maintenance dose.
Aspirin blocks platelet activation through a different pathway (COX-1 and thromboxane A2), while Prasugrel blocks the P2Y12 receptor. Using both can reduce stent thrombosis and recurrent events after acute coronary syndrome in selected patients. The downside is higher bleeding risk, so the planned duration of dual therapy is a medical decision, not a patient-led adjustment.
People with active bleeding, or a history of stroke or transient ischaemic attack, are generally not candidates for Prasugrel because bleeding risk can outweigh benefit. A planned major surgery can also change the timing or choice of antiplatelet therapy. If a patient has frequent falls, liver disease, or a prior bleeding ulcer, prescribers usually assess risk more conservatively.
Take the missed dose when you remember on the same day, then continue the next dose at the usual time. Do not double the next dose to “catch up,” because the extra antiplatelet effect mainly increases bleeding risk. Repeated missed doses after a recent stent are risky, so clinicians often prefer patients to build a reminder system early.
Many pain medicines increase bleeding risk when added to antiplatelets. NSAIDs such as ibuprofen, naproxen, and diclofenac are common culprits for stomach bleeding, especially when used for several days. For short-term fever or mild pain, prescribers often prefer options that do not affect platelets as much, based on the patient’s history and other medicines.
Black stools, vomiting blood, sudden severe headache, one-sided weakness, confusion, or fainting after a bleed are red flags. Blood in urine, heavy menstrual bleeding, or bleeding that will not stop also deserves urgent assessment. Mild bruising can be expected, but bleeding that escalates or is new after adding another medicine should be treated as significant.
Front view
Side view
Back view
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.
Prasugrel — Comparison with alternatives
Prasugrel Current Best price
Arjuna Best rated
Reviews and Experiences
Sources
- European Medicines Agency (EMA) (2026). Prasugrel: Summary of Product Characteristics (P2Y12 inhibitor antiplatelet therapy). ↑
- World Health Organization (WHO) (2026). Secondary prevention after acute coronary syndromes: antithrombotic therapy and cardiovascular risk reduction. ↑
- National Institute for Health and Care Excellence (NICE) (2026). Acute coronary syndromes: antiplatelet therapy recommendations and risk balancing. ↑
- National Agency for Food and Drug Administration and Control (NAFDAC) (2026). Guidance on safe use of prescription cardiovascular medicines and reporting adverse drug reactions. ↑
- European Medicines Agency (EMA) (2026). Prasugrel: Interaction and bleeding risk management in dual antiplatelet therapy. ↑